Eluminex Biosciences Acquires Zuretinol Acetate from Retinagenix Holdings
Eluminex announced today it acquired rights for a novel oral therapy to treat LCA or RP caused mutations of the RPE65 or LRAT gene.
top of page
RPE65
Disease Category: autosomal dominant
Patient Population: 1,000 - 2,000
Known Clinical Trials: yes, 3 recruiting
Potential Treatment: Luxturna
Strategies to Preserve Eye Health: Lutein
Institution(s) Conducting Research: Perelman School of Medicine |
Children’s Hospital of Philadelphia (CHOP) | UOC Oculistica, Milan |
Ospedale di Camposampiero | UOC Oculistica, Florence | Moorfields Eye Hospital | Kellogg Eye Center |
A FACE OF RP
Jack
U.S.A.
IN THE NEWS
ACADEMIC PAPERS | JOURNAL ARTICLES | PERSONAL STORIES
RPE65-associated inherited retinal diseases: consensus recommendations for eligibility to gene therapy
Andrea Sodi, Sandro Banfi, Michele Della Corte, Francesco Testa, Ilaria Passerini, Elisabetta Pelo, Settimio Rossi, and Francesca Simonelli | Orphanet Journal of Rare Diseases | Vol. 16 | Article 257 | 4 Jun 2021 |
Inherited retinal dystrophy caused by confirmed biallelic mutations in the RPE65 gene, which encodes all-trans retinyl ester isomerase, an enzyme critical to the visual cycle, is a serious and sight-threatening autosomal recessive genetic disorder that causes a severe form of rod-cone mediated IRD that eventually progresses to complete blindness.
The effect of human gene therapy for RPE65-associated Leber’s congenital amaurosis on visual function: a systematic review and meta-analysis
Xue Wang, Chaofeng Yu, Radouil T. Tzekov, Yihua Zhu, and Wensheng Li | Orphanet Journal of Rare Diseases | Vol 15 (49) | 14 Feb 2020 |
RPE65-associated LCA (RPE65-LCA) is an inherited retinal degeneration caused by the mutations of RPE65 gene and gene therapy has been developed to be a promising treatment. This study aims to evaluate the association between changes in visual function and application of gene therapy in patients with RPE65-LCA.
Hiroyuki Morimura, Gerald A. Fishman, Sandeep A. Grover, Anne B. Fulton, Eliot L. Berson, and
Thaddeus P. Dryja | PNAS | 17 Ma 1998 | Vol. 95 (6) |3088–3093 | doi: 10.1073/pnas.95.6.3088
To explore the possible role that defects in RPE65 might play in the etiology of retinal degenerations, we screened a large cohort of unrelated patients with retinitis pigmentosa or Leber congenital amaurosis for mutations. Because RPE65 is expressed specifically in the eye, the study focused on patients with nonsyndromic forms of these diseases.
Mutations in the RPE65 gene in patients with autosomal recessive retinitis pigmentosa or Leber congenital amaurosis
Advanced late-onset retinitis pigmentosa with dominant-acting D477G RPE65 mutation is responsive to oral synthetic retinoid therapy
Paul F Kenna, Marian M Humphries, Anna-Sophia Kiang, Philippe Brabet, Laurent Guillou, Ema Ozaki, Matthew Campbell, G Jane Farrar, Robert Koenekoop, Pete Humphries | BMJ Open Ophthalmology | 2020 | 5:e000462 | doi: 10.1136/bmjophth-2020-00046
Objectives No therapeutic interventions are currently available for autosomal dominant retinitis pigmentosa (adRP). An RPE65 Asp477Gly transition associates with late-onset adRP, reduced RPE65 enzymatic activity being one feature associated with this dominant variant. Our objective: to assess whether in a proof-of-concept study, oral synthetic 9 cis-retinyl acetate therapy improves vision in such advanced disease.
Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence
ADD NEW ARTICLE
Jie Gao, Rehan M Hussain, and Christina Y Weng | Clinical Ophthalmology | 13 Nov 2020 | Vol. 14 | 3855–3869 |doi: 10.2147/OPTH.S231804
Subretinal gene therapy trials began with the discovery of RPE65 variants and their association with Leber congenital amaurosis. The RPE65 protein is critical for the normal functioning of the visual phototransduction cascade. RPE65 gene knockout animal models were developed
bottom of page